|
Nivolumab for the treatment of renal-cell carcinoma |
Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L. Nivolumab for the treatment of renal-cell carcinoma. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 491. 2016 Authors' conclusions No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage.
High-quality evidence, coming from a single study in patients with clear cell histology, indicates that nivolumab would result in an additional benefit on overall survival of approximately six months, with better tolerance than the available comparators in patients with advanced renal-cell carcinoma who have progressed despite antiangiogenic therapy.
The coverage policies found all come from the United States private sponsors, providing coverage in patients with advanced renal-cell carcinoma which has progressed despite antiangiogenic therapy. In Canada, coverage is recommended only under and price-reduction agreement as it is not cost-effective at its current price.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Carcinoma, Renal Cell; Humans Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001111 Date abstract record published 25/11/2016 |
|
|
|